349 related articles for article (PubMed ID: 30415479)
1. The US Biosimilar Market: Stunted Growth and Possible Reforms.
Sarpatwari A; Barenie R; Curfman G; Darrow JJ; Kesselheim AS
Clin Pharmacol Ther; 2019 Jan; 105(1):92-100. PubMed ID: 30415479
[TBL] [Abstract][Full Text] [Related]
2. Why Are Biosimilars Not Living up to Their Promise in the US?
Zhai MZ; Sarpatwari A; Kesselheim AS
AMA J Ethics; 2019 Aug; 21(8):E668-678. PubMed ID: 31397662
[TBL] [Abstract][Full Text] [Related]
3. Biosimilars in the United States: Emerging Issues in Litigation.
Wong AY; Rumore MM; Chan AW
BioDrugs; 2017 Jun; 31(3):189-205. PubMed ID: 28424972
[TBL] [Abstract][Full Text] [Related]
4. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
Falit BP; Singh SC; Brennan TA
Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
[TBL] [Abstract][Full Text] [Related]
5. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
6. A Systematic Review of U.S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding?
Hung A; Vu Q; Mostovoy L
J Manag Care Spec Pharm; 2017 Dec; 23(12):1234-1244. PubMed ID: 29172975
[TBL] [Abstract][Full Text] [Related]
7. 10 years of biosimilars: lessons and trends.
Royzman I; Shah K
Nat Rev Drug Discov; 2020 Jun; 19(6):375. PubMed ID: 32358591
[No Abstract] [Full Text] [Related]
8. Biosimilars: the need, the challenge, the future: the FDA perspective.
Epstein MS; Ehrenpreis ED; Kulkarni PM;
Am J Gastroenterol; 2014 Dec; 109(12):1856-9. PubMed ID: 24957160
[TBL] [Abstract][Full Text] [Related]
9. Optimizing use and addressing challenges to uptake of biosimilars.
Leber MB
Am J Manag Care; 2018 Nov; 24(21 Suppl):S457-S461. PubMed ID: 30452214
[TBL] [Abstract][Full Text] [Related]
10. History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology.
Kalantar-Zadeh K
Am J Nephrol; 2017; 45(3):235-247. PubMed ID: 28142147
[TBL] [Abstract][Full Text] [Related]
11. The complexities of biosimilars and the regulatory approval process.
Lucio S
Am J Manag Care; 2018 Jun; 24(11 Suppl):S231-S236. PubMed ID: 29957908
[TBL] [Abstract][Full Text] [Related]
12. Understanding State Regulation of Biosimilars and Effect on Prescribers.
Yale K; Awosika O; Rengifo-Pardo M; Ehrlich A
J Drugs Dermatol; 2017 Oct; 16(10):995-1000. PubMed ID: 29036253
[TBL] [Abstract][Full Text] [Related]
13. Perspectives on the Current State of the Biosimilar Regulatory Pathway in the United States.
Dougherty MK; Zineh I; Christl L
Clin Pharmacol Ther; 2018 Jan; 103(1):36-38. PubMed ID: 29152721
[TBL] [Abstract][Full Text] [Related]
14. Biosimilars: The US Regulatory Framework.
Christl LA; Woodcock J; Kozlowski S
Annu Rev Med; 2017 Jan; 68():243-254. PubMed ID: 27813877
[TBL] [Abstract][Full Text] [Related]
15. Biologic Drugs, Biosimilars, and Barriers to Entry.
Shepherd JM
Health Matrix Clevel; 2015; 25():139-61. PubMed ID: 29485844
[TBL] [Abstract][Full Text] [Related]
16. Current market and regulatory landscape of biosimilars.
Bhatt V
Am J Manag Care; 2018 Nov; 24(21 Suppl):S451-S456. PubMed ID: 30452213
[TBL] [Abstract][Full Text] [Related]
17. The rise of biosimilars: How they got here and where they are going.
Patel D; Gillis C; Naggar J; Mistry A; Mantzoros CS
Metabolism; 2017 Oct; 75():45-53. PubMed ID: 28939017
[TBL] [Abstract][Full Text] [Related]
18. Biosimilar safety factors in clinical practice.
Reinisch W; Smolen J
Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products.
Moore TJ; Mouslim MC; Blunt JL; Alexander GC; Shermock KM
JAMA Intern Med; 2021 Jan; 181(1):52-60. PubMed ID: 33031559
[TBL] [Abstract][Full Text] [Related]
20. Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges.
Chapman K; Adjei A; Baldrick P; da Silva A; De Smet K; DiCicco R; Hong SS; Jones D; Leach MW; McBlane J; Ragan I; Reddy P; Stewart DI; Suitters A; Sims J
MAbs; 2016; 8(3):427-35. PubMed ID: 26854177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
